307. Higgins, S. C., A. G. Jarnicki, E. C. Lavelle, and K. H. Mills. 2006. TLR4 mediates vaccine-induced
protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. Journal of immunology
177:7980-7989.
308. Higgs, R., S. C. Higgins, P. J. Ross, and K. H. Mills. 2012. Immunity to the respiratory pathogen
Bordetella pertussis. Mucosal immunology 5:485-500.
309. McGuirk, P., C. McCann, and K. H. Mills. 2002. Pathogen-specific T regulatory 1 cells induced in the
respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. The Journal of experimental medicine 195:221-231.
310. Spensieri, F., G. Fedele, C. Fazio, M. Nasso, P. Stefanelli, P. Mastrantonio, and C. M. Ausiello. 2006.
Bordetella pertussis inhibition of interleukin-12 (IL-12) p70 in human monocyte-derived dendritic cells blocks IL-12 p35 through adenylate cyclase toxin-dependent cyclic AMP induction. Infection and immunity
74:2831-2838.
311. Hoeve, M. A., N. D. Savage, T. de Boer, D. M. Langenberg, R. de Waal Malefyt, T. H. Ottenhoff, and F. A. Verreck. 2006. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells.
European journal of immunology 36:661-670.
312. McGuirk, P., and K. H. Mills. 2000. Direct anti-inflammatory effect of a bacterial virulence factor: IL-
10-dependent suppression of IL-12 production by filamentous hemagglutinin from Bordetella pertussis. European journal of immunology 30:415-422.
313. Marth, T., and B. L. Kelsall. 1997. Regulation of interleukin-12 by complement receptor 3 signaling. The
Journal of experimental medicine 185:1987-1995.
314. Hickey, F. B., C. F. Brereton, and K. H. Mills. 2008. Adenylate cyclase toxin of Bordetella pertussis
inhibits TLR-induced IRF-1 and IRF-8 activation and IL-12 production and enhances IL-10 through MAPK activation in dendritic cells. Journal of leukocyte biology 84:234-243.
315. Sutterwala, F. S., Y. Ogura, M. Szczepanik, M. Lara-Tejero, G. S. Lichtenberger, E. P. Grant, J. Bertin, A. J. Coyle, J. E. Galan, P. W. Askenase, and R. A. Flavell. 2006. Critical role for NALP3/CIAS1/
Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24:317-327.
316. Dirix, V., V. Verscheure, T. Goetghebuer, M. Hainaut, A. S. Debrie, C. Locht, and F. Mascart. 2009.
Monocyte-derived interleukin-10 depresses the Bordetella pertussis- specific gamma interferon response in vaccinated infants. Clinical and vaccine immunology : CVI 16:1816-1821.
317. Ross, P. J., E. C. Lavelle, K. H. Mills, and A. P. Boyd. 2004. Adenylate cyclase toxin from Bordetella
pertussis synergizes with lipopolysaccharide to promote innate interleukin-10 production and enhances the induction of Th2 and regulatory T cells. Infection and immunity 72:1568-1579.
318. Nagamatsu, K., A. Kuwae, T. Konaka, S. Nagai, S. Yoshida, M. Eguchi, M. Watanabe, H. Mimuro, S. Koyasu, and A. Abe. 2009. Bordetella evades the host immune system by inducing IL-10 through a type
III effector, BopN. The Journal of experimental medicine 206:3073-3088.
319. Cassone, A., P. Mastrantonio, and C. M. Ausiello. 2000. Are only antibody levels involved in the
protection against pertussis in acellular pertussis vaccine recipients? The Journal of infectious diseases
182:1575-1577.
320. Mahon, B. P., M. T. Brady, and K. H. Mills. 2000. Protection against Bordetella pertussis in mice in the
absence of detectable circulating antibody: implications for long-term immunity in children. The Journal of infectious diseases 181:2087-2091.
321. Mooi, F. R., I. H. van Loo, M. van Gent, Q. He, M. J. Bart, K. J. Heuvelman, S. C. de Greeff, D. Diavatopoulos, P. Teunis, N. Nagelkerke, and J. Mertsola. 2009. Bordetella pertussis strains with
increased toxin production associated with pertussis resurgence. Emerging infectious diseases 15:1206-
1213.
322. Peppoloni, S., M. Pizza, M. T. De Magistris, A. Bartoloni, and R. Rappuoli. 1995. Acellular pertussis
vaccine composed of genetically inactivated pertussis toxin. Physiological chemistry and physics and medical NMR 27:355-361.
323. Robbins, J. B., R. Schneerson, B. Trollfors, H. Sato, Y. Sato, R. Rappuoli, and J. M. Keith. 2005. The
diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins. The Journal of infectious diseases 191:81-88.
324. di Tommaso, A., M. T. de Magistris, M. Bugnoli, I. Marsili, R. Rappuoli, and S. Abrignani. 1994.
Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing. Infection and immunity 62:1830-1834.
325. Paddock, C. D., G. N. Sanden, J. D. Cherry, A. A. Gal, C. Langston, K. M. Tatti, K. H. Wu, C. S. Goldsmith, P. W. Greer, J. L. Montague, M. T. Eliason, R. C. Holman, J. Guarner, W. J. Shieh, and S. R. Zaki. 2008. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clinical
infectious diseases : an official publication of the Infectious Diseases Society of America 47:328-338.
326. Pierce, C., N. Klein, and M. Peters. 2000. Is leukocytosis a predictor of mortality in severe pertussis
infection? Intensive care medicine 26:1512-1514.
of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model. Infection and immunity 74:6797-6805.
328. Geurtsen, J., F. Fransen, R. J. Vandebriel, E. R. Gremmer, L. J. de la Fonteyne-Blankestijn, B. Kuipers, J. Tommassen, and P. van der Ley. 2008. Supplementation of whole-cell pertussis vaccines
with lipopolysaccharide analogs: modification of vaccine-induced immune responses. Vaccine 26:899-
906.
329. Abe, A., K. Nagamatsu, and M. Watanabe. 2008. The Bordetella type III secretion system: its application
to vaccine development. Microbiology and immunology 52:128-133.
330. Sawa, T., T. L. Yahr, M. Ohara, K. Kurahashi, M. A. Gropper, J. P. Wiener-Kronish, and D. W. Frank.
1999. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nature medicine 5:392-398.
331. Medhekar, B., R. Shrivastava, S. Mattoo, M. Gingery, and J. F. Miller. 2009. Bordetella Bsp22 forms a
filamentous type III secretion system tip complex and is immunoprotective in vitro and in vivo. Molecular microbiology 71:492-504.
332. Villarino Romero, R., I. Bibova, O. Cerny, B. Vecerek, T. Wald, O. Benada, J. Zavadilova, R. Osicka, and P. Sebo. 2013. The Bordetella pertussis type III secretion system tip complex protein Bsp22 is not
a protective antigen and fails to elicit serum antibody responses during infection of humans and mice. Infection and immunity 81:2761-2767.
333. Cerca, N., T. Maira-Litran, K. K. Jefferson, M. Grout, D. A. Goldmann, and G. B. Pier. 2007. Protection
against Escherichia coli infection by antibody to the Staphylococcus aureus poly-N-acetylglucosamine surface polysaccharide. Proceedings of the National Academy of Sciences of the United States of America
104:7528-7533.
334. Martinez, L. R., and A. Casadevall. 2005. Specific antibody can prevent fungal biofilm formation and this
effect correlates with protective efficacy. Infection and immunity 73:6350-6362.
335. Visai, L., C. R. Arciola, G. Pietrocola, S. Rindi, P. Olivero, and P. Speziale. 2007. Staphylococcus
biofilm components as targets for vaccines and drugs. The International journal of artificial organs 30:813-
819.
336. Mielcarek, N., A. S. Debrie, D. Raze, J. Bertout, C. Rouanet, A. B. Younes, C. Creusy, J. Engle, W. E. Goldman, and C. Locht. 2006. Live attenuated B. pertussis as a single-dose nasal vaccine against
2